← 프로그램 목록
ADCPhase 3Recruiting

T-DXd (Trastuzumab-Deruxtecan)

RocheGenentech

비교

Trastuzumab-Deruxtecan (T-DXd)(Roche / Genentech)은 Breast Cancer 표적 ADC로, Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting hormone receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 79.7% (ClinicalTrials.gov NCT03529110). 차별점: novel DXd-ADC technology using DXd, a derivative of the topoisomerase I inhibitor exatecan, as its payload.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 8일 (6일 전)PK/독성 2026년 7월 8일 (6일 전)

Breast Cancer

Breast Cancer

Recruiting

Technology

구조모아 · Exatecan/DXd (TOP1)

ADC) is a next-generation antibody therapeutics designed to del

deruxtecan (Dato-DXd, Datroway ® )]

cleavable peptide linker and a topoisomerase I payload with byst

humanized antibodies and, subsequently, fully human antibodies for cancer therapy, thereby avoiding the side

novel DXd-ADC technology using DXd, a derivative of the topoisomerase I inhibitor exatecan, as its payload

Mechanism of Action

targeting hormone receptor

topoisomerase I inhibitor exatecan, as its payload

TROP2 on cancer cell surface and, follow

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 83건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: N/A · Phase 3 · Phase 1, Phase 2 · Phase 2, Phase 3
  • Status: Recruiting · Active, not recruiting
  • 주요 endpoint: Real World Time to Next Treatment (rwTTNT1) in Participants With Unresectable and/or Metastatic Breast Cancer · Type of Treatment Patterns in Participants With Unresectable and/or Metastatic Breast Cancer · Number of Physician-reported Safety Events of Interest in Participants With Unresectable and/or Metastatic Breast Cancer (T-DXd only) · Number of Participants Receiving Prophylactic and Reactive Treatment Management for Physician-reported Safety Events of Interest in Participants With Unresectable and/or Metastatic Breast Cancer (T-DXd only) · Real World Time to Permanent Treatment Discontinuation (rwTTD1) in Participants With Unresectable and/or Metastatic Breast Cancer
  • 등록된 결과: ORR 79.7%
  • PFS: NA
  • 핵심: This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Trastuzumab-Deruxtecan (T-DXd)은 어떤 치료제인가요?
Trastuzumab-Deruxtecan (T-DXd)(Roche / Genentech)은 Breast Cancer 표적 ADC로, Breast Cancer 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Trastuzumab-Deruxtecan (T-DXd)의 임상 단계는?
Trastuzumab-Deruxtecan (T-DXd)의 현재 단계는 Phase 3입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.